Condition (MeSH)
Ectodermal Dysplasia
ClinicalTrials.gov lists 53 trials for Ectodermal Dysplasia or a narrower condition beneath it. Edimer Pharmaceuticals has the most among industry and government lead sponsors, with 13.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
10 of the 53 trials are tagged with Ectodermal Dysplasia itself; the rest are tagged with a narrower condition beneath it.
When did Ectodermal Dysplasia trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 1 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ectodermal Dysplasia trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 4 |
| Observational | 34 |
How many Ectodermal Dysplasia trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 9 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 30 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ectodermal Dysplasia trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Edimer Pharmaceuticals | 13 |
| Palvella Therapeutics, Inc. | 4 |
| Orvida Pharma (formerly Kamari Pharma) | 2 |
| AstraZeneca | 1 |
| Dermelix Biotherapeutics, LLC. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Ectodermal Dysplasia? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EDI200 | 4 |
| Nicotinamide Riboside | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| PTX-022 | 3 |
| Vital signs | 2 |
| Jojoba oil with broccoli sprout extract | 1 |
| 1% Azithromycin | 1 |
| TD101 | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Ectodermal Dysplasia? (19)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. | Genes | 2023 | Yes |
| A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement. | International journal of molecular sciences | 2023 | Yes |
| TSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study. | American journal of medical genetics. Part A | 2021 | Yes |
| Behavioral functioning in cardiofaciocutaneous syndrome: Risk factors and impact on parenting experience. | American journal of medical genetics. Part A | 2016 | Yes |
| Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. | British journal of cancer | 2015 | Yes |
Showing 5 of 19 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Ectodermal dysplasia syndrome | Point prevalence | 6-9 / 10 000 | Worldwide | Not stated | Exact |
| Ectodermal dysplasia syndrome | Point prevalence | 6-9 / 10 000 | Worldwide | Not stated | Exact |
| Ectodermal dysplasia syndrome | Point prevalence | 6-9 / 10 000 | Worldwide | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Ectodermal dysplasia syndrome | 79373 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Ectodermal dysplasia syndrome | 79373 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (5)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials.